A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology

[1]  C. Lambalk,et al.  Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. , 2014, Human reproduction.

[2]  M. Hill,et al.  The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. , 2012, Fertility and sterility.

[3]  R. Fischer,et al.  Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case–control study , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  M. Hill,et al.  Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. , 2012, Reproductive biomedicine online.

[5]  L. Gianaroli,et al.  ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. , 2011, Human reproduction.

[6]  C. Simón,et al.  Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. , 2011, Fertility and sterility.

[7]  O. Naether,et al.  A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[8]  M. Kupka,et al.  Summary of the 2008 Annual Report of the German IVF Registry , 2010 .

[9]  F. Broekmans,et al.  Ovarian aging: mechanisms and clinical consequences. , 2009, Endocrine reviews.

[10]  Rita Agostinetto.  Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment , 2009, Reproductive biology and endocrinology : RB&E.

[11]  J. Remohi,et al.  The impact of luteinizing hormone supplementaion in gonadotropin releasing hormone antagonist cycles. An age adjusted randomized trail , 2008 .

[12]  D. Ezcurra,et al.  Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats , 2008, Reproductive biology and endocrinology : RB&E.

[13]  O. Papasouliotis,et al.  Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. , 2008, Current medical research and opinion.

[14]  M. van Wely,et al.  Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. , 2007, The Cochrane database of systematic reviews.

[15]  R. Fischer.  Understanding the role of LH: myths and facts. , 2007, Reproductive biomedicine online.

[16]  L. Gianaroli,et al.  Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. , 2004, Fertility and sterility.

[17]  P. Humaidan,et al.  Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. , 2004, Reproductive biomedicine online.

[18]  G. Cognigni,et al.  Current concepts and novel applications of LH activity in ovarian stimulation , 2003, Trends in Endocrinology & Metabolism.

[19]  D. Goldhamer,et al.  Reproductive Biology and Endocrinology , 2003 .

[20]  P. Pearson,et al.  The variability of female reproductive ageing. , 2002, Human reproduction update.

[21]  T. N. M. V. Rooij,et al.  RecDate - eine IT-Lösung für die Dokumentation und Qualitätssicherung reproduktionsmedizinischer Behandlungen , 2001 .

[22]  T. van Rooij,et al.  [RecDate - an IT-solution for the documentation and quality management of reproductive medicine]. , 2001, Zentralblatt fur Gynakologie.

[23]  A. Andersen,et al.  Maternal age and fetal loss: population based register linkage study , 2000, BMJ : British Medical Journal.

[24]  T. E. R. H. L. S. Group.  Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  Robert L. Quails.  The board of trustees , 1983 .